Skip to main content

Table 3 Relationships between clinicopathological characteristics of PTC patients and BRAFV600E mutation status and BANCR and miR-9 expression in carcinoma tissue (n = 51)

From: BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features

  BRAFV600E mutation (n) P value BANCR (n) P value miR-9 (n) P value
Yes No > 0.01 ≤ 0.01 > 0.01 ≤ 0.01
Sex    0.471    0.742    0.475
 Female 27 10   26 11   20 17  
 Male 12 2   9 5   6 8  
Age (years)    0.497    0.221    0.180
 ≤ 45 23 9   20 12   14 18  
 > 45 16 3   15 4   12 7  
Tumor location    < 0.001    0.654    0.645
 Unilateral 9 11   13 7   11 9  
 Bilateral 30 1   22 9   15 16  
Tumor size (cm/mean) 1.8 ± 0.7 1.3 ± 0.4 0.002 1.7 ± 0.8 1.5 ± 0.6 0.501 1.6 ± 0.8 1.7 ± 0.7 0.756
Multifocality    0.003    0.510    0.104
 Single 7 8   9 6   5 10  
 Multiple (≥ 2) 32 4   26 10   21 15  
Extracapsular invasion    0.004    0.036    0.121
 No 14 10   13 11   15 9  
 Yes 25 2   22 5   11 16  
Extrathyroid extension    0.173    0.694    0.140
 No 31 12   30 13   24 19  
 Yes 8 0   5 3   2 6  
Hashimoto’s disease    0.616    0.363    0.419
 No 35 10   32 13   24 21  
 Yes 4 2   3 3   2 4  
Central LNM    0.101    0.202    0.012
 No 12 7   12 6   14 5  
 Yes 27 5   23 10   12 20  
Lateral LNM    0.042    0.033    0.029
 No 23 11   20 14   21 13  
 Yes 16 1   15 2   5 12  
TNM stage    0.110    0.470    0.291
 T1 17 9   16 10   15 11  
 T2 14 3   12 5   9 8  
 T3 8 0   7 1   2 6  
  1. BANCR BRAF-activated long non-coding RNA, LNM lymph node metastasis, TNM tumor-node-metastasis